
    
      Sixty eligible patients with periodontal defect will randomly receive either beta-TCP
      implantation (control group) or PERIOGEN implantation, containing beta-TCP and rhPDGF (drug
      group). The specified primary and secondary end points related to efficacy and safety will be
      assessed during 6 months study period.
    
  